Deeksha Vishwamitra

1.2k total citations
27 papers, 492 citations indexed

About

Deeksha Vishwamitra is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Deeksha Vishwamitra has authored 27 papers receiving a total of 492 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 12 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Deeksha Vishwamitra's work include Multiple Myeloma Research and Treatments (11 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Protein Degradation and Inhibitors (5 papers). Deeksha Vishwamitra is often cited by papers focused on Multiple Myeloma Research and Treatments (11 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Protein Degradation and Inhibitors (5 papers). Deeksha Vishwamitra collaborates with scholars based in United States, Germany and China. Deeksha Vishwamitra's co-authors include Hesham M. Amin, Ping Shi, Elizabeth G. Demicco, Joseph A. Ludwig, Antonios G. Mikos, Mary C. Farach‐Carson, Brian A. Menegaz, Eliza Li Shan Fong, Salah-Eddine Lamhamedi-Cherradi and Vandhana Ramamoorthy and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Deeksha Vishwamitra

23 papers receiving 487 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Deeksha Vishwamitra United States	11	214	191	142	121	71	27	492
Mahshid Saleh Iran	11	207 1.0×	187 1.0×	91 0.6×	119 1.0×	83 1.2×	22	676
Cynthia S. Snyder United States	13	255 1.2×	178 0.9×	235 1.7×	81 0.7×	104 1.5×	22	733
Shima Uneda Japan	11	264 1.2×	189 1.0×	40 0.3×	124 1.0×	50 0.7×	17	495
Lourdes Cortes‐Dericks Germany	15	192 0.9×	212 1.1×	97 0.7×	74 0.6×	117 1.6×	18	603
Rakesh Bam United States	12	174 0.8×	111 0.6×	89 0.6×	47 0.4×	34 0.5×	25	411
Thuy Trinh Germany	11	194 0.9×	147 0.8×	56 0.4×	92 0.8×	129 1.8×	20	501
Karl‐Ludwig Schäfer Germany	12	268 1.3×	241 1.3×	157 1.1×	100 0.8×	111 1.6×	13	637
Takahiro Heishi Japan	10	298 1.4×	206 1.1×	41 0.3×	118 1.0×	82 1.2×	16	586
Yang Xun China	12	192 0.9×	100 0.5×	36 0.3×	60 0.5×	132 1.9×	38	499
Roberto Verardo Italy	10	196 0.9×	215 1.1×	66 0.5×	91 0.8×	184 2.6×	16	537

Countries citing papers authored by Deeksha Vishwamitra

Since Specialization

Citations

This map shows the geographic impact of Deeksha Vishwamitra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deeksha Vishwamitra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deeksha Vishwamitra more than expected).

Fields of papers citing papers by Deeksha Vishwamitra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deeksha Vishwamitra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deeksha Vishwamitra. The network helps show where Deeksha Vishwamitra may publish in the future.

Co-authorship network of co-authors of Deeksha Vishwamitra

This figure shows the co-authorship network connecting the top 25 collaborators of Deeksha Vishwamitra. A scholar is included among the top collaborators of Deeksha Vishwamitra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deeksha Vishwamitra. Deeksha Vishwamitra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Popat, Rakesh, Alexa M. G. A. Laheij, Niels W.C.J. van de Donk, et al.. (2025). Prophylactic interventions for oral toxicities with the GPRC5D×CD3 bispecific antibody talquetamab in relapsed/refractory multiple myeloma: An update on the open-label, phase 2, randomized TALISMAN study.. Journal of Clinical Oncology. 43(16_suppl).

Rasche, Leo, Carolina Schinke, Cyrille Touzeau, et al.. (2024). Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S240–S240. 5 indexed citations

Garfall, Alfred L., Ajay K. Nooka, Philippe Moreau, et al.. (2024). Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S235–S235.

Schinke, Carolina, Cyrille Touzeau, Monique C. Minnema, et al.. (2024). P-098 Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S99–S99.

Garfall, Alfred L., Ajay K. Nooka, Philippe Moreau, et al.. (2024). MM-336 Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S548–S548. 8 indexed citations

Rasche, Leo, Carolina Schinke, Cyrille Touzeau, et al.. (2024). MM-492 Long-term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S561–S562. 9 indexed citations

Popat, Rakesh, Ajay K. Nooka, Niels W.C.J. van de Donk, et al.. (2024). P-067 Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S80–S80. 1 indexed citations

Popat, Rakesh, Alexa M. G. A. Laheij, Niels W.C.J. van de Donk, et al.. (2024). P-066 Prophylactic Interventions for Oral Toxicities With the GPRC5D×CD3 Bispecific Antibody Talquetamab in Relapsed/Refractory Multiple Myeloma: An Open-Label, Phase 2, Randomized Study (TALISMAN). Clinical Lymphoma Myeloma & Leukemia. 24. S79–S80. 1 indexed citations

Song, Qingxuan, Deeksha Vishwamitra, Nikoletta Lendvai, et al.. (2024). Preclinical Analysis of Ciltacabtagene Autoleucel Combination Strategies with T Cell Bispecifics and Daratumumab to Support Optimization of Clinical Benefit in Myeloma Patients. Blood. 144(Supplement 1). 7167–7167.

10.

Garfall, Alfred L., Ajay K. Nooka, Niels W.C.J. van de Donk, et al.. (2024). Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma.. Journal of Clinical Oncology. 42(16_suppl). 7540–7540. 26 indexed citations

11.

Kaseb, Ahmed O., Abedul Haque, Deeksha Vishwamitra, et al.. (2022). Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma. Frontiers in Oncology. 12. 986305–986305. 16 indexed citations

12.

Rubnitz, Jeffrey E., Thomas Alexander, Theodore W. Laetsch, et al.. (2020). Venetoclax and Navitoclax in Pediatric Patients with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Blood. 136(Supplement 1). 12–13. 1 indexed citations

13.

Falchook, Gerald S., Deeksha Vishwamitra, Takayuki Yamada, et al.. (2017). Abstract CT100: First-in-human phase 1 trial of pyrimidine anti-metabolite FF-10502-01 in patients with advanced cancer. Cancer Research. 77(13_Supplement). CT100–CT100. 1 indexed citations

14.

Vishwamitra, Deeksha, Choladda V. Curry, Serhan Alkan, et al.. (2015). The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK+ T-cell lymphoma. Molecular Cancer. 14(1). 22 indexed citations

15.

Vishwamitra, Deeksha, Choladda V. Curry, Ping Shi, Serhan Alkan, & Hesham M. Amin. (2015). SUMOylation Confers Posttranslational Stability on NPM-ALK Oncogenic Protein. Neoplasia. 17(9). 742–754. 10 indexed citations

16.

Falchook, Gerald S., Jennifer J. Wheler, Aung Naing, et al.. (2014). Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab. Oncotarget. 5(21). 10280–10292. 47 indexed citations

17.

Shi, Bin, et al.. (2013). Molecular and Functional Characterizations of the Association and Interactions between Nucleophosmin-Anaplastic Lymphoma Kinase and Type I Insulin-Like Growth Factor Receptor. Neoplasia. 15(6). 669–IN24. 12 indexed citations

18.

Zhu, Haifeng, et al.. (2013). NPM‐ALK up‐regulates iNOS expression through a STAT3/microRNA‐26a‐dependent mechanism. The Journal of Pathology. 230(1). 82–94. 24 indexed citations

19.

Fong, Eliza Li Shan, Salah-Eddine Lamhamedi-Cherradi, Vandhana Ramamoorthy, et al.. (2013). Modeling Ewing sarcoma tumors in vitro with 3D scaffolds. Proceedings of the National Academy of Sciences. 110(16). 6500–6505. 184 indexed citations

20.

Vishwamitra, Deeksha, Yong Li, Choladda V. Curry, et al.. (2012). MicroRNA 96 Is a Post-Transcriptional Suppressor of Anaplastic Lymphoma Kinase Expression. American Journal Of Pathology. 180(5). 1772–1780. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact